Bioregulators Khavinson Cluster

What this cluster is — the honest framing first

These thirteen peptides are members of the Khavinson short-peptide bioregulator family — a body of Russian work that’s one of the most interesting and one of the most contested things in the peptide world. You can’t write about any single member honestly without setting the framework up front, so here it is, both sides.

Origin. The program began in 1970s Soviet military medicine at the Military Medical Academy in Leningrad. Researchers extracted tissue-specific peptide fractions from animal organs: thymus, prostate, liver, vessel wall, bronchial lining, and others — and observed bioactive effects when those fractions were re-administered, particularly in aged tissue. Vladimir Khavinson became the central figure; after 1991 the St. Petersburg Institute of Bioregulation and Gerontology became the program’s institutional home. The first-generation products were polypeptide complexes extracted directly from tissue (Thymalin from thymus is the prototype). The second generation are synthetic short peptides — di-, tri-, and tetrapeptides — designed to reproduce the active fragment of the original extract (Vilon, Thymagen, Bronchogen, Prostamax, and the rest).

The theoretical claim. Short peptides (2–4 amino acids) are small enough to cross the cell and nuclear membranes, bind specific DNA promoter regions, and modulate transcription in a tissue-specific way — each peptide’s sequence claimed to act as a “regulatory signal” for the regeneration of the organ it was originally extracted from. Thymalin/Thymagen/Vilon → thymus and immune tissue; Cardiogen → heart; Bronchogen/Chonluten → lung; Prostamax → prostate; and so on. There is real in-vitro work behind the binding claim: short Khavinson peptides have been shown to penetrate HeLa-cell nuclei and interact with DNA and with deoxyribooligonucleotides (Fedoreyeva et al. 2011, Biochemistry (Mosc), 22117547), and to drive heterochromatin decondensation and reactivate silenced genes in lymphocytes from elderly subjects (Khavinson, Lezhava, Malinin 2004, Bull Exp Biol Med, 15085253).

Western reception is split: and both sides are true.

• The conventional Western position: preclinical-only for most members; the human studies that exist are small, single-research-group, often unblinded, and methodologically weak by Western RCT standards; the gene-regulation mechanism is heterodox and under-replicated outside the Khavinson ecosystem.
• The Russian/Eastern-European position: a 50-year sustained, internally-consistent research program with consistent reported outcomes, and several members (Thymalin and the cortex peptide Cortexin) actually approved for clinical use in Russia. The thinness of the Western RCT base is partly structural — these are non-patentable molecules with no pharma sponsor to fund Phase 3 trials.

OHM’s lean, per doctrine: report both honestly. Don’t dismiss a 50-year body of work because it’s Russian-school and animal-heavy: animal and in-vitro data are first-class evidence here. Don’t overclaim it either: for most of these thirteen, the human efficacy data genuinely does not exist yet, and we say so. The mechanism is interesting; the Western-replication gap is real; both statements are correct at the same time. The 0035 categorization pass landed exactly there: Thymalin, Thymagen, and Vilon were promoted to Tier C / Safety Green (recommend-eligible on the Russian record), while the other ten were kept provisional / D-pending: encyclopedia-only, because their individual human evidence doesn’t warrant a recommendation.

Immune / thymus group — Thymalin, Thymagen, Vilon

This is the strongest-evidenced corner of the whole family and the only corner the 0035 pass made recommend-eligible. All three target the thymus and immune system, and all three sit at Tier C / Safety Green.

Thymalin

What it is. The prototype of the entire family: a polypeptide complex extracted from thymus tissue, not a single synthetic sequence. Profiled by thepeptidelist.com under anti-aging (secondary: immune), evidence tier Moderate (30 studies cited, 19 human). It’s also one of the Khavinson peptides with an actual Russian clinical-use approval.

Claimed mechanism. Thymus-derived peptides supporting T-cell development and immune-system function — restoring immune competence in the aging (involuting) thymus.

What the research shows. This is the deepest human record in the family, though all of it is Russian cohort work with zero RCTs, and per KB doctrine every third-party citation below carries until the citation pass confirms it:

• Khavinson & Morozov 2003, Neuro Endocrinol Lett — 266 elderly patients, 6–8 yr; Thymalin + Epithalamin reported to reduce mortality 2.0–4.1 fold. 14523363.
• Khavinson & Morozov 2002, Adv Gerontol — same cohort, geroprotective effect. 12577695.
• Shustval’ 1992, Lik Sprava — 156 patients; normalized lipid metabolism + improved cardiac function in ischemic heart disease. 1481512.
• COVID-19 era: Thymalin added to standard therapy reported to accelerate decline in IL-6/CRP/D-dimer and reduce thrombosis risk (Khavinson, Kuznik et al. 2021, Stem Cell Rev Rep, 33575961), with a reported COVID-19 mortality of 20.6% in a Thymalin+Tocilizumab cohort (Kuznik et al. 2022, Adv Gerontol, 36169363).
• In-vitro: reductions in pro-inflammatory cytokines 1.4–6.0×; up to 6.8-fold increases in CD28 expression on T lymphocytes.

The honest read: a genuinely substantial human dataset by Russian-school standards: far deeper than anything else in this cluster — but no blinded RCT, and Western reviewers discount the cohort designs. That is the both-sides position. OHM grade: C / green — PRIMARY longevity, SECONDARY immune.

Thymagen (Glu-Trp / EW)

What it is. A synthetic dipeptide (Glu-Trp) framed as the short-peptide successor to Thymalin: same thymic/immune target, distilled to two amino acids. Site tier Emerging (1 study, 0 human).

Claimed mechanism. Stimulates thymic epithelial-cell activity → supports T-cell maturation and differentiation in the aging thymus.

What the research shows. Thin and in-vitro only: Thymagen (alongside Thymalin and Vilosen) affected cAMP/cGMP levels and phosphodiesterase activity in spleen lymphocytes during sensitization/anaphylaxis (Demidov et al. 1991, Ukr Biokhim Zh, 1659006). OHM grade: C / green: PRIMARY immune, SECONDARY longevity (promoted on the Khavinson-school rationale and benign safety, not on study volume).

Vilon (Lys-Glu / KE)

What it is. A synthetic dipeptide (Lys-Glu / KE), the immune/geroprotective member with the most human studies after Thymalin. Site tier graded Strong (20 studies, 3–6 human — the site’s own counts are internally inconsistent), highest trial phase listed as Phase 3.

Claimed mechanism. Influences thymic gene expression and immune-cell development; in the chromatin work it behaves like the rest of the family — selective heterochromatin decondensation and gene reactivation in elderly lymphocytes.

What the research shows. Russian human cohorts plus a strong in-vitro chromatin/epigenetics line (all):

• Kuznik et al. 2007, Adv Gerontol — improved coagulation + immune markers and reduced insulin requirements in elderly diabetics. 18306698.
• Kuznik et al. 2006 — reduced DIC syndrome in type-1 diabetes. 17152731.
• Ias’kevich et al. 2005 — improved survival / fewer complications in elderly stage-III colorectal cancer patients. 16075684 case series.
• Epigenetic in-vitro: the “KE peptide” (Vilon) increased SIRT1 and decreased PARP1/PARP2 expression in aging human MSCs (Khavinson, Linkova et al. 2023, Adv Gerontol, 37782636); selective heterochromatin decondensation in elderly lymphocytes (Lezhava et al. 2023, Georgian Med News, 37042594).

OHM grade: C / green: SECONDARY longevity + SECONDARY immune (no PRIMARY: the 0035 pass judged the per-indication evidence too thin to anchor a primary goal, despite the higher study count).

Immune-group cross-link. The thymic-immune target here overlaps conceptually with Thymosin Alpha-1 — a separate, far better Western-evidenced thymic immune peptide (a 28-amino-acid fragment of thymosin, with real human trial data and active research-vendor availability). If a reader lands here looking for a thymus/immune peptide they can actually buy from a verified-COA vendor today, Thymosin alpha-1 is the better-evidenced answer; the Khavinson thymic trio is the deeper-history, Russian-school context around it.

---

Vascular group — Cardiogen, Vesugen

Both target the cardiovascular system; both are D / provisional, encyclopedia-only. This is also where the source data needs the most caution, because of name-collisions in the directory’s auto-citation.

Cardiogen

What it is. A Khavinson bioregulator peptide targeting cardiomyocytes — claimed to modulate gene expression for cardiac contractility and tissue maintenance. Site tier listed Moderate (12 studies, 9 human).

Important source caveat. The “9 human studies” the directory attaches to Cardiogen are not about the peptide — they’re about “CardioGen-82,” a rubidium-82 PET imaging generator, plus an unrelated Hungarian “Szeged CardioGen” cardiomyopathy registry (e.g. 28110572, 22393230). This is a directory auto-matching artifact, not real Cardiogen-peptide evidence. The honest read: the Cardiogen peptide itself has no meaningful human evidence base — treat the site’s “Moderate / 9 human” grade as spurious and the peptide as preclinical/anecdotal like the rest of the organ line. Flagged and corrected here.

OHM grade: D / provisional: encyclopedia-only.

Vesugen (Lys-Glu-Asp / KED)

What it is. A Khavinson tripeptide targeting vascular endothelium — claimed to modulate gene expression for angiogenesis, endothelial repair, and vascular tone. Site tier Anecdotal (0 studies cited, 0 human). No structured study list exists on the source. Genuinely the thinnest evidence in the group: purely framework-level. OHM grade: D / provisional.

---

Respiratory group — Bronchogen, Chonluten

Both target the lung; both D / provisional. Bronchogen is the better-supported of the two and one of the better-supported of the whole provisional set, on animal data.

Bronchogen (Ala-Asp-Glu-Leu / AEDL)

What it is. A Khavinson tetrapeptide (Ala-Asp-Glu-Leu) targeting bronchial epithelium. Site tier Emerging (7 studies, 0 human).

What the research shows. Real preclinical signal in a COPD model (all):

• Reduced lung inflammation and restored bronchial-epithelium structure in a COPD rat model (Titova et al. 2017, 30199201; Kuzubova et al. 2015, Bull Exp Biol Med, 26468022).
• Increased DNA thermostability / DNA-stabilizing properties for the AEDL sequence (Monaselidze et al. 2011, 21240358) — this is the citation that pins the sequence.

The COPD-model data is the most concrete organ-regeneration signal in the provisional set. Still animal-only; no human work. OHM grade: D / provisional.

Chonluten

What it is. A Khavinson short peptide targeting lung epithelium and mucosal barrier. Site tier Anecdotal (1 study, 0 human). The single citation: peptides (including Chonluten) modulating proliferative activity and inflammatory pathways (TNF, IL-6) in the THP-1 monocyte/macrophage line (Avolio, Martinotti, Khavinson et al. 2022, Int J Mol Sci, 35408963). OHM grade: D / provisional.

---

Digestive / hepatic group — Pancragen, Ovagen, Livagen

All three target the gut/liver/pancreas axis; all D / provisional.

Pancragen (Lys-Glu-Asp-Trp / KEDW)

A Khavinson tetrapeptide for the pancreas — claimed to act at gene-promoter regions in pancreatic cells, modulating insulin-secretion and beta-cell-maintenance proteins. Site tier Anecdotal with 0 studies cited — “no published clinical studies were found on PubMed.” Framework-level only. The metabolic/beta-cell angle is the interesting hook if it ever gets real data, but right now there is none. OHM grade: D / provisional.

Ovagen

A Khavinson tripeptide the source profiles for liver and GI tissue (hepatocyte function, GI mucosal health): not, despite the name, ovarian tissue. Site tier Emerging (22 studies, 1 human).

Important source caveat. The 22 cited studies are all bovine/ovine/caprine superovulation and embryo-production papers (FSH, follicular dynamics in ewes and beef cows): a clear name-collision between “Ovagen” the Khavinson liver peptide and “ovagen/ovulation” veterinary reproduction literature the directory auto-matched. None of those citations are evidence for the Ovagen peptide. The honest read: the Ovagen peptide’s actual human/preclinical evidence base is effectively empty; treat it as framework-level like Livagen. Flagged and corrected here. (This is also why the build brief lists Ovagen under both “digestive” and “reproductive” — the name straddles both, but the peptide is the liver/GI one.) OHM grade: D / provisional.

Livagen (Lys-Glu-Asp-Ala / KEDA)

A Khavinson tetrapeptide for the liver — claimed to promote chromatin decondensation in hepatocytes, reactivating silenced genes (consistent with the family’s chromatin-remodeling in-vitro line, e.g. Khavinson/Lezhava/Malinin 2004, 15085253). Site tier Anecdotal (0 studies cited for Livagen specifically). OHM grade: D / provisional.

---

Reproductive / hormone group — Testagen, Prostamax

Both target the reproductive axis; both D / provisional, both with the family-typical chromatin in-vitro data and no human efficacy data.

Testagen (Lys-Glu-Asp-Gly / KEDG)

A synthetic peptide framed for testicular tissue and natural testosterone support. Site tier Anecdotal (2 studies, 0 human). The two citations are off-target for the testosterone claim: a copper-corrosion-inhibition study of the Testagen peptide in saline (Dobriţescu et al. 2025, Molecules, 40807317) and a generic short-peptide nuclear-penetration / DNA-interaction study (Fedoreyeva et al. 2011, 22117547), both. There is no human testosterone data for Testagen — the hormone-support framing is mechanistic claim, not measured outcome. OHM grade: D / provisional.

Prostamax (Lys-Glu-Asp-Pro / KEDP)

A Khavinson tetrapeptide for the prostate. Site tier Anecdotal (4 studies, 0 human). The four citations are all the family’s chromatin/heterochromatin in-vitro work in senile/elderly lymphocytes — increased sister-chromatid exchanges and pericentromeric heterochromatin decondensation (Dzhokhadze et al. 2012, 23221144; Khavinson/Lezhava/Malinin 2004, 15085253; plus 19359734, 15612551), all. These demonstrate the family mechanism, not a prostate-specific clinical effect — there are no prostate-outcome human studies. OHM grade: D / provisional.

---

General / longevity group — Cartalax

Cartalax (Ala-Glu-Asp-Gly / AEDG)

A Khavinson peptide for cartilage and connective tissue, profiled under anti-aging. Site tier Anecdotal with 0 studies cited — purely framework-level. Notable mainly as the family’s “musculoskeletal” member; the AEDG sequence and the cartilage-maintenance claim are the community-circulated story, but there’s no captured study behind either, so both are. OHM grade: D / provisional.

---

Real-world protocol — the honest state

Educational purposes only — this is what the Russian-school protocols and the peptide community actually use, stated plainly, so you have the real numbers; it is not medical advice.

There is no Western-validated dosing protocol for any of these thirteen. What exists is the Khavinson-school cycle pattern, consistent across the family and shared with the better-documented members Epithalon and the Cognitive peptides cluster — Dihexa, Pinealon, Cortagen pair (Pinealon/Cortagen):

• Cycle structure (the family signature): a short course: typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year. The framework claims effects persist 2–3 months past the end of a cycle (the “epigenetic-like persistence” rationale for cycling rather than continuous dosing) — this persistence claim is asserted by the Khavinson program and not independently confirmed.
• Synthetic short peptides (Thymagen, Vilon, Bronchogen, Prostamax, etc.): community subcutaneous dosing converges around ~100–200 mcg/day for the di/tetrapeptides over the 10–20 day cycle; some are also sold as oral capsules and sublingual drops in the Russian retail market per-peptide specifics.
• Thymalin (the extract): historically given as a small IM injection over a short in-clinic course in the Russian protocols exact mg.
• Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within ~28 days — the same handling as any peptide in this KB.

Because per-peptide human dose-finding data does not exist for this family, treat every number above as community/Russian-protocol convergence, not a validated dose. The 0035 pass rated the whole family Safety Green where it rated it at all (benign profiles, no serious adverse events reported in the Russian literature) — but that’s Russian-source pharmacovigilance only, and long-term repeated-cycle safety in humans is not characterized in Western data.

Side effects & the real risk

The reported adverse-event profile across the family is mild and uncommon in the Russian literature: occasional injection-site reactions, transient mild headache early in a cycle. No serious AEs documented at standard doses.

The real risk with this family isn’t the molecule: it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category. The typical buyer is sourcing a Russian-school peptide from a forum link with no way to verify identity or purity, and counterfeit/mislabeled product is the most common failure mode for exactly these compounds. That makes third-party COA verification matter more here than for almost any other class — not because the peptides are dangerous, but because you can’t trust that what’s in the vial is what’s on the label without it.

Regulatory status

All thirteen are research_only in the US — not FDA-approved for human use, sold as research compounds, not eligible for compounding (per each profile). None is a controlled substance. Thymalin and the related cortex peptide Cortexin hold clinical-use approvals in Russia; that approval does not extend to the US.

The Alyve / commercial layer

None of these thirteen is in Alyve’s 15-SKU launch catalog. This article is encyclopedia / authority content — it exists to be the credible, honest map of the Russian organ-peptide family, which is itself a conversion asset: being the source that tells the truth about a confusing, heavily-counterfeited category builds the trust that routes readers to verified product elsewhere on the site.

The one genuinely relevant commercial cross-link is the thymic-immune overlap: a reader who arrives here wanting a thymus/immune peptide they can actually buy from a verified-COA vendor today is better served by Thymosin Alpha-1 — far stronger Western evidence, real human trials, and live research-vendor availability — than by the Khavinson thymic trio, which is the deeper-history context around it. That’s the honest hand-off, and it doesn’t require inventing a CTA for compounds Alyve doesn’t sell.

The broader Alyve trust story still anchors the conversation, and it’s the whole reason the counterfeit problem above matters: US-manufactured + third-party Freedom Diagnostics COAs + >99% purity verified across the launch catalog + identity-confirmed. For a category where counterfeit product is the default failure mode, a verified-COA vendor isn’t a luxury — it’s the entire point of buying from a vendor rather than a forum.

Use code OHM-15 for 15% off: Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. While the Khavinson line isn’t in the catalog, the same bulk logic powers the SKUs that are — a 3-vial block of BPC-157, GHK-Cu, or TB-500 crosses the bulk threshold at the highest discount tier.

Sources

• thymagen.md, testagen.md, prostamax.md, pancragen.md, ovagen.md, cardiogen.md, bronchogen.md, chonluten.md, cartalax.md, livagen.md, vilon.md, vesugen.md — primary per-peptide profiles (thepeptidelist.com directory captures, 2026-06-07). Every third-party citation drawn from them is tagged per KB doctrine.
• the OHM tier/safety/goal grading: Thymalin / Thymagen / Vilon promoted to C-green; Livagen / Ovagen / Pancragen / Prostamax / Testagen / Cartalax / Chonluten / Bronchogen / Cardiogen / Vesugen kept D-provisional / encyclopedia-only; the explicit recommendation to build “a single wiki article describing the framework, not 11 separate ones.”
• Cross-references: Cognitive peptides cluster — Dihexa, Pinealon, Cortagen (the Khavinson framework section, plus Pinealon/Cortagen — sister members), Epithalon (the flagship longevity member), Thymosin Alpha-1 (the better-evidenced, buyable thymic-immune alternative).

Related: Epithalon · Cognitive peptides cluster — Dihexa, Pinealon, Cortagen · Thymosin Alpha-1 · BPC-157 · GHK-Cu · TB-500.